Chung Moon-Koo, Han Sang-Seop, Kim Jong-Choon
Korea Institute of Toxicology, KRICT, Yuseong, Daejeon 305-600, South Korea, Republic of Korea.
Regul Toxicol Pharmacol. 2006 Aug;45(3):273-81. doi: 10.1016/j.yrtph.2006.05.004. Epub 2006 Jun 30.
This study examined the potential adverse effects of a new camptothecin anticancer agent, CKD-602, on the fertility and early embryonic development of Sprague-Dawley rats. Ninety-six rats of each gender were divided into four groups: three treatment groups and a control group. CKD-602 was administered intravenously to male rats at 0, 4.7, 14, and 42 microg/kg from 63 days prior to mating until the end of the mating period, and to female rats from 14 days before mating until day 6 of gestation. All the males were sacrificed after the end of the 14-day mating period, while all the females were subjected to a caesarean section on day 15 of gestation. In the high dose group, a high incidence of hair loss was observed in both genders. A decrease in the level of food consumption, followed by a decrease in body weight gain was also observed in both genders. At the scheduled necropsy, the gross postmortem examinations revealed an increase in the incidence of thymic atrophy, paleness of the thoracic and abdominal organs in both genders and an increase in the serum testosterone concentration. In addition, there was a decrease in the thymus weight of the males and an increase in the liver, spleen, kidneys, lung, and heart weights of the females. There was an increase in the number of fetal deaths and post-implantation losses as well as a decrease in the litter size found at the caesarean section of the dams. No treatment-related effect on the histopathological findings, sexual cycle, pre-coital time, mating index, fertility index, pregnancy index, and sperm parameters was observed. There were no adverse effects on the general findings and reproductive performance of the parent animals and early embryonic development in the low and medium dose groups. Overall, the no-observed-adverse-effect levels (NOAELs) of CKD-602 are believed to be 14 microg/kg for both general toxicity and early embryonic development, and more than 42 microg/kg for the reproductive performance of the parent animals.
本研究考察了一种新型喜树碱类抗癌药物CKD - 602对Sprague-Dawley大鼠生育能力及早期胚胎发育的潜在不良影响。将96只雄性和96只雌性大鼠分为四组:三个治疗组和一个对照组。在交配前63天至交配期结束,对雄性大鼠静脉注射CKD - 602,剂量分别为0、4.7、14和42微克/千克;对雌性大鼠在交配前14天至妊娠第6天静脉注射CKD - 602。在14天交配期结束后处死所有雄性大鼠,在妊娠第15天对所有雌性大鼠进行剖腹产。高剂量组中,雌雄两性均出现高发生率的脱发。雌雄两性均观察到食物摄入量减少,随后体重增加减少。在预定的尸检中,大体尸检显示两性胸腺萎缩发生率增加、胸腹部器官苍白,血清睾酮浓度升高。此外,雄性大鼠胸腺重量减轻,雌性大鼠肝脏、脾脏、肾脏、肺和心脏重量增加。剖腹产时发现死胎数和着床后损失增加,窝仔数减少。未观察到与治疗相关的对组织病理学结果、性周期、交配前时间、交配指数、生育指数、妊娠指数和精子参数的影响。低剂量组和中剂量组对亲代动物的一般表现和生殖性能以及早期胚胎发育均无不良影响。总体而言,CKD - 602的未观察到不良作用水平(NOAELs)对于一般毒性和早期胚胎发育均被认为是14微克/千克,对于亲代动物的生殖性能则大于42微克/千克。